Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for Relapsed/Refractory Multiple Myeloma
NCT05259839Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Oct 2022
- Primary completion
- Sep 2033
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 1, open-label trial of etentamig in multiple myeloma (MM) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Dose Limiting Toxicities at 28 days and Adverse Events at 3 years. Started Oct 2022; status: active, not recruiting.
02
Drugs
etentamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05259839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05259839.